Oncotelic Therapeutics, a clinical-stage biopharmaceutical company focused on oncology and immunotherapy, is advancing its drug pipeline toward late-stage development and commercialization. This progress aligns with industry trends where value creation is concentrated in assets nearing market approval, enhancing company valuation due to reduced risk and clearer revenue prospects. Oncotelic also benefits from a strong patent portfolio and joint ventures, such as its 45% stake in GMP Bio, which complement its strategic position in oncology and rare disease therapeutics. These developments position Oncotelic to capitalize on the growing demand for innovative cancer treatments.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
SpaceX shares fell below their IPO price of $135 for the first time, dropping to $132.28 before closing slightly above at $135.27. The stock is down about 16% from its June 12 closing price and 36% from its peak on June 16. The decline reflects inves...
Aave has deployed its latest V4 lending protocol on the Avalanche blockchain, marking the first time this version runs outside Ethereum. This launch extends Aave's new Hub and Spoke architecture to Avalanche, where older V3 markets already exist. Whi...
